Loading clinical trials...

Strategic Use of New Generation Antidepressants for Depression | Clinical Trials | Clareo Health

COMPLETEDPhase 4NCT01109693

Strategic Use of New Generation Antidepressants for Depression

The purpose of the study is to establish the optimum treatment strategy for first-line and second-line antidepressants in the acute phase treatment of major depression.

Lead sponsor: Kyoto University•2 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Trial snapshot

StatusCOMPLETED

PhasePHASE4

Enrollment2,011

Start dateDec 2010

Last updatedOct 3, 2016

Condition

Unipolar Major Depressive Episode

Locations shown

Nagoya City University Hospital

Nagoya, Aichi-ken

Kochi Medical School Hospital

Nangoku, Kochi

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 3, 2016Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions